Morgan Stanley Stock News

Morgan Stanley boosted its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 1,107.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,129,478 shares of the companys stock after purchasing an additional 1,035,898 shares during the period. Morgan Stanley owned about 0.79% of []

Morgan Stanley lessened its stake in Invesco China Technology ETF (NYSEARCA:CQQQ) by 2.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 346,011 shares of the companys stock after selling 9,918 shares during the period. Morgan Stanleys holdings in Invesco China Technology ETF were worth $29,134,000 at the []

Morgan Stanley reduced its holdings in H&R Block, Inc. (NYSE:HRB) by 23.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,240,597 shares of the companys stock after selling 389,601 shares during the quarter. Morgan Stanley owned about 0.68% of H&R Block []

Hookipa Pharma (NASDAQ:HOOK) was downgraded by stock analysts at Morgan Stanley from an overweight rating to an equal weight rating in a research note issued on Friday, Price Targets.com reports. They currently have a $6.00 target price on the stock. Morgan Stanleys price objective suggests a potential upside of 43.88% from the stocks previous close. []

Banco Bilbao Vizcaya Argentaria (NYSE:BBVA) was upgraded by research analysts at Morgan Stanley from an equal weight rating to an overweight rating in a research note issued to investors on Friday, The Fly reports. A number of other research analysts have also recently weighed in on BBVA. UBS Group reaffirmed a neutral rating on shares []

Peel Hunt restated their hold rating on shares of B&M European Value Retail (LON:BME) in a research note released on Thursday morning, Price Targets.com reports. They currently have a GBX 575 ($7.51) price objective on the stock. BME has been the topic of several other reports. Morgan Stanley raised their target price on shares of []

Agiliti (NYSE:AGTI) had its price objective hoisted by KeyCorp from $23.00 to $27.00 in a research report sent to investors on Wednesday, PriceTargets.com reports. The firm currently has an overweight rating on the stock. A number of other brokerages also recently issued reports on AGTI. Morgan Stanley increased their price target on Agiliti from $21.00 []

(PR-inside.com) RADNOR, PA / ACCESSWIRE / November 13, 2021 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a class action lawsuit has been filed against Goldman Sachs Group Inc. ("Goldman Sachs") and Morgan Stanley (collectively, "Defendants"), charging both companies with violations of the federal securities laws, including insider trading, relating to their unlawful disposal of Gaotu Techedu Inc. ("Gaotu") (NYSE:GOTU) American Depository Shares. Defendants'' unlawful sales of Gaotu shares allowed them collectively to avoid billions in losses while investors suffered significantly. IF YOU ARE HAVING TROUBLE VIEWING THE VIDEO ABOVE, PLEASE CLICK HERE CLICK HERE TO SUBMIT ..